Synthetic control of mammalian-cell motility by engineering chemotaxis to an orthogonal bioinert chemical signal

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 16, 2014, Pages 5896-5901

  Park, Jason S ^a,b,c   Rhau, Benjamin ^a,b   Hermann, Aynur ^a,b   McNally, Krista A ^a,b   Zhou, Carmen ^a,b   Gong, Delquin ^b,d   Weiner, Orion D ^b,d   Conklin, Bruce R ^a,b,c,d   Onuffer, James ^a,b   Lim, Wendell A ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GLADSTONE INSTITUTE OF CARDIOVASCULAR DISEASE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cellular therapeutics; GPCR; Synthetic biology

Indexed keywords

CLOZAPINE N OXIDE; G PROTEIN COUPLED RECEPTOR; MICROSPHERE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL MIGRATION; CELL STRAIN HL 60; CHEMOTAXIS; CONTROLLED STUDY; DNA MODIFICATION; ENDOTHELIUM CELL; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; MONOLAYER CULTURE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SYNTHETIC BIOLOGY; T LYMPHOCYTE;

CELLULAR THERAPEUTICS; GPCR; SYNTHETIC BIOLOGY;

ADMINISTRATION, INTRAVENOUS; ANIMALS; CELL POLARITY; CHEMOTAXIS; CLOZAPINE; GENETIC ENGINEERING; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; HL-60 CELLS; HUMANS; MAMMALS; MICE; NEUTROPHILS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION;

EID: 84899084091     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1402087111     Document Type: Article

References (55)

1. Tang Q, Bluestone JA, Kang S-M (2012) CD4(+)Foxp3(+) regulatory T cell therapy in transplantation. J Mol Cell Biol 4(1):11-21.
2. Burrell BE, Nakayama Y, Xu J, Brinkman CC, Bromberg JS (2012) Regulatory T cell induction, migration, and function in transplantation. J Immunol 189(10):4705-4711.
3. Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: Harnessing the T cell response. Nat Rev Immunol 12(4):269-281.
4. Riddell SR, et al. (1992) Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257(5067):238-241.
5. Lu P, et al. (2012) Long-distance growth and connectivity of neural stem cells after severe spinal cord injury. Cell 150(6):1264-1273.
6. Bliss T, Guzman R, Daadi M, Steinberg GK (2007) Cell transplantation therapy for stroke. Stroke 38(2, Suppl):817-826. (Pubitemid 46188256)
7. Kershaw MH, et al. (2002) Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther 13(16):1971-1980. (Pubitemid 35341038)
8. Moon EK, et al. (2011) Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res 17(14):4719-4730.
9. Ankrum J, Karp JM (2010) Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol Med 16(5):203-209.
10. Cohen PJ, Lotze MT, Roberts JR, Rosenberg SA, Jaffe ES (1987) The immunopathology of sequential tumor biopsies in patients treated with interleukin-2: Correlation of response with T-cell infiltration and HLA-DR expression. Am J Pathol 129(2):208-216. (Pubitemid 18007974)
11. Cole DJ, et al. (1994) Histopathological analysis of metastatic melanoma deposits in patients receiving adoptive immunotherapy with tumor-infiltrating lymphocytes. Cancer Immunol Immunother 38(5):299-303. (Pubitemid 24128007)
12. Pockaj BA, et al. (1994) Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy: Augmentation with cyclophosphamide and correlation with response. Cancer 73(6):1731-1737.
13. Galon J, et al. (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960-1964. (Pubitemid 44498003)
14. Tosolini M, et al. (2011) Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 71(4):1263-1271.
15. Mitchell MS, et al. (2002) Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol 20(4):1075-1086. (Pubitemid 34141853)
16. Craddock JA, et al. (2010) Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother 33(8):780-788.
17. Di Stasi A, et al. (2009) T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 113(25):6392-6402.
18. Karp JM, Leng Teo GS (2009) Mesenchymal stem cell homing: The devil is in the details. Cell Stem Cell 4(3):206-216.
19. Rosenberg SA, et al. (1994) Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86(15):1159-1166. (Pubitemid 24249302)
20. Armbruster BN, Li X, Pausch MH, Herlitze S, Roth BL (2007) Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc Natl Acad Sci USA 104(12):5163-5168. (Pubitemid 47186193)
21. Conklin BR, et al. (2008) Engineering GPCR signaling pathways with RASSLs. Nat Methods 5(8):673-678.
22. Nakajima K, Wess J (2012) Design and functional characterization of a novel, arrestin-biased designer G protein-coupled receptor. Mol Pharmacol 82(4):575-582.
23. Bender D, Holschbach M, Stöcklin G (1994) Synthesis of n.c.a. carbon-11 labelled clozapine and its major metabolite clozapine-N-oxide and comparison of their biodistribution in mice. Nucl Med Biol 21(7):921-925. (Pubitemid 24324155)
24. Ray RS, et al. (2011) Impaired respiratory and body temperature control upon acute serotonergic neuron inhibition. Science 333(6042):637-642.
25. Neptune ER, Bourne HR (1997) Receptors induce chemotaxis by releasing the beta-gamma subunit of Gi, not by activating Gq or Gs. Proc Natl Acad Sci USA 94(26):14489-14494.
26. Fischbach MA, Bluestone JA, Lim WA (2013) Cell-based therapeutics: The next pillar of medicine. Sci Transl Med 5(179):ps7.
27. Rosenberg SA (2012) Raising the bar: The curative potential of human cancer immunotherapy. Sci Transl Med 4(127):ps8.
28. Rabinovich BA, et al. (2008) Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci USA 105(38):14342-14346.
29. Allen TM, Cullis PR (2013) Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev 65(1):36-48.
30. Rubin JT, Elwood LJ, Rosenberg SA, Lotze MT (1989) Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Cancer Res 49(24 Pt 1):7086-7092. (Pubitemid 20016597)
31. Ogawa M, et al. (1997) Enhanced induction of very late antigen 4/lymphocyte function-associated antigen 1-dependent T-cell migration to tumor sites following administration of interleukin 12. Cancer Res 57(11):2216-2222. (Pubitemid 27247041)
32. Pagès F, et al. (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353(25):2654-2666. (Pubitemid 41817714)
33. Musha H, et al. (2005) Selective infiltration of CCR5(+)CXCR3(+) T lymphocytes in human colorectal carcinoma. Int J Cancer 116(6):949-956. (Pubitemid 41209203)
34. Ohta M, et al. (2005) The high expression of Fractalkine results in a better prognosis for colorectal cancer patients. Int J Oncol 26(1):41-47.
35. Peled A, et al. (1999) Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 283(5403):845-848.
36. Imitola J, et al. (2004) Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1alpha/CXC chemokine receptor 4 pathway. Proc Natl Acad Sci USA 101(52):18117-18122. (Pubitemid 40054083)
37. Wagner J, Kean T, Young R, Dennis JE, Caplan AI (2009) Optimizing mesenchymal stem cell-based therapeutics. Curr Opin Biotechnol 20(5):531-536.
38. De Palma M, Murdoch C, Venneri MA, Naldini L, Lewis CE (2007) Tie2-expressing monocytes: Regulation of tumor angiogenesis and therapeutic implications. Trends Immunol 28(12):519-524.
39. Lewis CE, Pollard JW (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res 66(2):605-612. (Pubitemid 43165918)
40. Folcher M, Fussenegger M (2012) Synthetic biology advancing clinical applications. Curr Opin Chem Biol 16(3-4):345-354.
41. Khalil AS, Collins JJ (2010) Synthetic biology: Applications come of age. Nat Rev Genet 11(5):367-379.
42. Ruoslahti E, Bhatia SN, Sailor MJ (2010) Targeting of drugs and nanoparticles to tumors. J Cell Biol 188(6):759-768.
43. Stephan MT, Moon JJ, Um SH, Bershteyn A, Irvine DJ (2010) Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med 16(9):1035-1041.
44. Yoo J-W, Irvine DJ, Discher DE, Mitragotri S (2011) Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov 10(7):521-535.
45. Sarkar D, et al. (2011) Engineered cell homing. Blood 118(25):e184-e191.
46. Lutolf MP, Hubbell JA (2005) Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat Biotechnol 23(1)47-55. (Pubitemid 41724624)
47. Homey B, Müller A, Zlotnik A (2002) Chemokines: Agents for the immunotherapy of cancer? Nat Rev Immunol 2(3):175-184. (Pubitemid 37328764)
48. Chada S, Ramesh R, Mhashilkar AM (2003) Cytokine- and chemokine-based gene therapy for cancer. Curr Opin Mol Ther 5(5):463-474. (Pubitemid 37304711)
49. Tan MCB, et al. (2009) Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol 182(3):1746-1755.
50. Penn MS, et al. (2013) An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure. Circ Res 112(5):816-825.
51. Abastado J-P (2012) The next challenge in cancer immunotherapy: Controlling T-cell traffic to the tumor. Cancer Res 72(9):2159-2161.
52. Hong M, et al. (2011) Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res 71(22):6997-7009.
53. Wu YI, et al. (2009) A genetically encoded photoactivatable Rac controls the motility of living cells. Nature 461(7260):104-108.
54. Yoo SK, et al. (2010) Differential regulation of protrusion and polarity by PI3K during neutrophil motility in live zebrafish. Dev Cell 18(2):226-236.
55. Levskaya A, Weiner OD, Lim WA, Voigt CA (2009) Spatiotemporal control of cell signalling using a light-switchable protein interaction. Nature 461(7266):997-1001.